Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Flu activity rises sharply across US with 7.5 million cases, CDC data shows - 2Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- 3Ergonomic Office Seats for Work spaces
- 4'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- 5Vote in favor of your #1 Kind of Cap
- Rick Steves Recommends This German Town's Castle Hotel With Rhine River Views
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Most loved Well known Accessory Styles For 2024
- Parents who delay baby's first vaccines also likely to skip measles shots
- Poll: By a 2-to-1 margin, Americans say Trump has done more to raise prices than lower them
- The Job of a Land Legal counselor in Property Exchanges
- Strength training is crucial after menopause. How to make the most of your workouts
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
